Database : MEDLINE
Search on : Prostatic and Hyperplasia [Words]
References found : 24406 [refine]
Displaying: 1 .. 10   in format [Detailed]

page 1 of 2441 go to page                         

  1 / 24406 MEDLINE  
              next record last record
select
to print
Photocopy
Full text

[PMID]: 29501675
[Au] Autor:Park E; Lee MY; Jeon WY; Seo CS; You S; Shin HK
[Ad] Address:K-herb Research Center, Korea Institute of Oriental Medicine, 1672 Yuseong-daero, Yuseong-gu, Daejeon 34054, Republic of Korea. Electronic address: eunsook@kiom.re.kr.
[Ti] Title:Paljung-San, a traditional herbal medicine, attenuates benign prostatic hyperplasia in vitro and in vivo.
[So] Source:J Ethnopharmacol;218:109-115, 2018 Mar 06.
[Is] ISSN:1872-7573
[Cp] Country of publication:Ireland
[La] Language:eng
[Ab] Abstract:ETHNOPHARMACOLOGICAL RELEVANCE: Paljung-san is a traditional herbal medicine used widely for the treatment of urogenital diseases in East Asia. However, scientific evidence of the efficacy of Paljung-san and its mechanisms of action against benign prostatic hyperplasia (BPH) is not clearly established. AIM OF THE STUDY: We investigated the inhibitory effect of Paljung-san water extract (PSWE) and its mechanisms against BPH in vitro and in vivo. MATERIALS AND METHODS: Active compounds of PSWE were analyzed quantitatively by High-performance liquid chromatography (HPLC). For in vitro study, PSWE treated BPH-1 cells were used to perform western blot analysis, cell cycle analysis and enzyme-linked immunosorbent assay. For in vivo BPH model, male rats were subcutaneously injected with 10 mg/kg of testosterone propionate (TP) every day for four weeks. 200 and 500 mg/kg of PSWE was administrated daily by oral gavage with s.c. injection of TP, respectively. RESULTS: HPLC revealed that PSWE contains 1.21, 1.18, 2.27, 3.56, 4.23, 3.00, 6.78, and 0.004 mg/g of gallic acid, 5-caffeoylquinic acid, chlorogenic acid, geniposide, liquiritin apioside, liquiritin, glycyrrhizin, and chrysophanol components, respectively. In human BPH-1 cells, PSWE treatment reduced cell proliferation through arresting the cell cycle in the DNA synthesis phase. Moreover, PSWE suppressed prostaglandin E production with reduced cyclooxygenase-2 expression. In TP -induced BPH rat model, PSWE administration showed reduced prostate weights and dihydrotestosterone levels and led to a restoration of normal prostate morphology. PSWE also decreased TP-induced Ki-67 and cyclin D1 protein levels in the prostatic tissues. Decreased glutathione reductase activity and increased malondialdehyde levels in the BPH groups were reversed by PSWE administration. CONCLUSION: PSWE attenuates the progression of BPH through anti-proliferative, anti-inflammatory and anti-oxidant activities in vitro and in vivo. Therefore, these data provide the scientific evidence of pharmacological efficacy of PSWE against BPH.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180310
[Lr] Last revision date:180310
[St] Status:Publisher

  2 / 24406 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29329895
[Au] Autor:Cho MC; Song WH; Park J; Cho SY; Jeong H; Oh SJ; Paick JS; Son H
[Ad] Address:Department of Urology, Seoul National University Boramae Medical Center, Seoul, Korea.
[Ti] Title:Long-Term Outcomes of Laser Prostatectomy for Storage Symptoms: Comparison of Serial 5-Year Followup Data between 120 W High Performance System Photoselective Vaporization of the Prostate and Holmium Laser Enucleation of the Prostate.
[So] Source:J Urol;, 2018 Jan 09.
[Is] ISSN:1527-3792
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:PURPOSE: We compared long-term storage symptom outcomes between photoselective laser vaporization of the prostate with a 120 W high performance system and holmium laser enucleation of the prostate. We also determined factors influencing postoperative improvement of storage symptoms in the long term. MATERIALS AND METHODS: Included in our study were 266 men, including 165 treated with prostate photoselective laser vaporization using a 120 W high performance system and 101 treated with holmium laser enucleation of the prostate, on whom 60-month followup data were available. Outcomes were assessed serially 6, 12, 24, 36, 48 and 60 months postoperatively using the I-PSS (International Prostate Symptom Score), uroflowmetry and the serum prostate specific antigen level. Postoperative improvement in storage symptoms was defined as a 50% or greater reduction in the subtotal storage symptom score at each followup visit after surgery compared to baseline. RESULTS: Improvements in frequency, urgency, nocturia, subtotal storage symptom scores and the quality of life index were maintained up to 60 months after photoselective laser vaporization or holmium laser enucleation of the prostate. There was no difference in the degree of improvement in storage symptoms or the percent of patients with postoperative improvement in storage symptoms between the 2 groups throughout the long-term followup. However, the holmium laser group showed greater improvement in voiding symptoms and quality of life than the laser vaporization group. On logistic regression analysis a higher baseline subtotal storage symptom score and a higher BOOI (Bladder Outlet Obstruction Index) were the factors influencing the improvement in storage symptoms 5 years after prostate photoselective laser vaporization or holmium laser enucleation. CONCLUSIONS: Our serial followup data suggest that storage symptom improvement was maintained throughout the long-term postoperative period for prostate photoselective laser vaporization with a 120 W high performance system and holmium laser enucleation without any difference between the 2 surgeries. Also, more severe storage symptoms at baseline and a more severe BOOI predicted improved storage symptoms in the long term after each surgery.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1801
[Cu] Class update date: 180310
[Lr] Last revision date:180310
[St] Status:Publisher

  3 / 24406 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29523809
[Au] Autor:Nair-Shalliker V; Bang A; Weber M; Goldsbury DE; Caruana M; Emery J; Banks E; Canfell K; O'Connell DL; Smith DP
[Ad] Address:Cancer Research Division, Cancer Council NSW, Sydney, NSW, Australia.
[Ti] Title:Factors associated with prostate specific antigen testing in Australians: Analysis of the New South Wales 45 and Up Study.
[So] Source:Sci Rep;8(1):4261, 2018 Mar 09.
[Is] ISSN:2045-2322
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:Australia has one of the highest incidence rates of prostate cancer (PC) worldwide, due in part to widespread prostate specific antigen (PSA) testing. We aimed to identify factors associated with PSA testing in Australian men without a diagnosis of prostate cancer or prior prostate disease. Participants were men joining the 45 and Up Study in 2006-2009, aged ≥45 years at recruitment. Self-completed questionnaires were linked to cancer registrations, hospitalisations, health services data and deaths. Men with a history of PC, radical prostatectomy or a "monitoring" PSA test for prostate disease were excluded. We identified Medicare reimbursed PSA tests during 2012-2014. Multivariable logistic regression was used to estimate adjusted odds ratios (OR) for the association between having PSA tests and factors of interest. Of the 62,765 eligible men, 51.8% had at least one screening PSA test during 2012-2014. Factors strongly associated with having a PSA test included having 27+ general practitioner consultations (versus 3-9 consultations; OR = 2.00; 95%CI = 1.90-2.11), benign prostatic hyperplasia treatment (versus none; OR = 1.59(95%CI = 1.49-1.70), aged 60-69 years (versus 50-59 years; OR = 1.54; 95%CI = 1.48-1.60). These results emphasise the important role of primary care in decision making about PSA testing.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180310
[Lr] Last revision date:180310
[St] Status:In-Data-Review
[do] DOI:10.1038/s41598-018-22589-y

  4 / 24406 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy

[PMID]: 29376615
[Au] Autor:Kamalov AA; Takhirzade AM
[Ad] Address:Department of Urology and Andrology, Faculty of Fundamental Medicine, Lomonosov MSU, Moscow, Russia.
[Ti] Title:[Current approaches to conservative treatment of men with concomitant benign prostatic hyperplasia and erectile dysfunction].
[So] Source:Urologiia;(6):160-163, 2017 Dec.
[Is] ISSN:1728-2985
[Cp] Country of publication:Russia (Federation)
[La] Language:rus
[Ab] Abstract:The article reviews the results of various conservative treatments for concomitant benign prostatic hyperplasia (BPH) and erectile dysfunction (ED). Phosphodiesterase type 5 (PDE5) inhibitors remain the first-line therapy for this category of patients taking into account their positive effect on both ED and BPH. The preferred treatment scheme includes PDE-5 inhibitor co-administered with 1-adrenoblocker. However, other combination treatments are considered promising, for example, a PDE-5 inhibitor with a 5-reductase inhibitor or a three-component treatment regimen: 1-adrenoblocker + 5-reductase inhibitor + PDE-5 inhibitor. All these approaches to treating patients with BPH and ED have demonstrated high efficiency and safety. Nevertheless, a limited number of randomized clinical trials and short-term observations suggest the need for further studies investigating the long-term outcomes of different treatment options for such patients.
[Mh] MeSH terms primary: 5-alpha Reductase Inhibitors/therapeutic use
Adrenergic alpha-1 Receptor Antagonists/therapeutic use
Erectile Dysfunction
Phosphodiesterase 5 Inhibitors/therapeutic use
Prostatic Hyperplasia
[Mh] MeSH terms secundary: Erectile Dysfunction/drug therapy
Erectile Dysfunction/etiology
Erectile Dysfunction/pathology
Erectile Dysfunction/physiopathology
Humans
Male
Prostatic Hyperplasia/complications
Prostatic Hyperplasia/drug therapy
Prostatic Hyperplasia/pathology
Prostatic Hyperplasia/physiopathology
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Nm] Name of substance:0 (5-alpha Reductase Inhibitors); 0 (Adrenergic alpha-1 Receptor Antagonists); 0 (Phosphodiesterase 5 Inhibitors)
[Em] Entry month:1803
[Cu] Class update date: 180309
[Lr] Last revision date:180309
[Js] Journal subset:IM
[Da] Date of entry for processing:180130
[St] Status:MEDLINE

  5 / 24406 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy

[PMID]: 29376601
[Au] Autor:Orlov IN; Popov SV; Martov AG; Gallyamov EA; Malevich SM; Sushina IV; Grin EA; Sanzharov AE; Novikov AB; Sergeev VP; Kochkin AD
[Ad] Address:St. Lukes Clinical Hospital, St. Petersburg, Russia.
[Ti] Title:[Comparative assessment of treatments for prostate adenoma greater than 100 cm3].
[So] Source:Urologiia;(6):82-86, 2017 Dec.
[Is] ISSN:1728-2985
[Cp] Country of publication:Russia (Federation)
[La] Language:rus
[Ab] Abstract:AIM: To compare holmium laser enucleation of the prostate (HoLEP) and endovideosurgical (EVS) adenomectomy in the treatment of prostate adenoma. MATERIALS AND METHODS: We compared treatment results of 180 patients with prostate adenomas greater than 100 cm3 who underwent EVS adenomectomy (n=90) and laser enucleation of the prostate (n=90). The analysis included the following parameters: duration of catheterization, length of postoperative hospital stay, I-PSS score, maximum urinary flow rate measured by uroflowmetry and complications according to Clavien-Dindo grading systems. RESULTS: There were no significant differences in patient age, preoperative prostate size, glandular tissue weight, and operative time. The duration of catheterization (p=0.0008) and length of postoperative hospital stay (p<0.0001) were significantly shorter in the HoLEP group. Both groups showed a statistically significant improvement in functional performance at three months post-surgery. Complications in the HoLEP and EVS adenomectomy group occurred in 18 (20%) and 23 (25.55%) patients, respectively (p>0.99). CONCLUSION: The two methods mentioned above are widely used in the treatment of prostate adenoma. However, holmium laser enucleation of the prostate shows similar short-term functional results and complication rates compared with EVS adenomectomy for prostate adenomas greater than 100 cm3. The patients of the HoLEP group had better results regarding the duration of catheterization and length of postoperative hospital stay. Therefore, laser enucleation is the preferred surgical modality for prostate adenomas greater than 100 cm3.
[Mh] MeSH terms primary: Laser Therapy/methods
Length of Stay
Prostate/surgery
Prostatic Hyperplasia/surgery
Video-Assisted Surgery/methods
[Mh] MeSH terms secundary: Aged
Humans
Male
Prostate/pathology
Prostatic Hyperplasia/pathology
[Pt] Publication type:CLINICAL TRIAL; COMPARATIVE STUDY; JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180309
[Lr] Last revision date:180309
[Js] Journal subset:IM
[Da] Date of entry for processing:180130
[St] Status:MEDLINE

  6 / 24406 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy

[PMID]: 29376600
[Au] Autor:Biktimirov RG; Martov AG; Biktimirov TR; Kaputovskii AA
[Ad] Address:Federal Clinical Center for High Medical Technologies FMBA of Russia, Moscow Region, Khimki, Russia.
[Ti] Title:[The role of extraperitoneoscopic adenomectomy in the management of benign prostatic hyperplasia greater than 80 cm3].
[So] Source:Urologiia;(6):76-81, 2017 Dec.
[Is] ISSN:1728-2985
[Cp] Country of publication:Russia (Federation)
[La] Language:rus
[Ab] Abstract:INTRODUCTION: The current standard of surgery for benign prostatic hyperplasia (BPH) greater than 80 cm3 includes open adenomectomy and holmium enucleation. Transurethral resection and laser vaporization are second line interventions, while the role of laparoscopic extraperitoneal adenomectomy is not fully understood. AIM: To evaluate the role of laparoscopic technique as a surgical modality for BPH greater than 80 cm3. MATERIALS AND METHODS: This study retrospectively evaluated the results of 79 patients (mean age 68 years) who underwent transcapsular extraperitoneoscopic adenomectomy from 2011 to 2016. RESULTS: The mean operative time was 206 (100-450) min; the prostate volume was 134 (80-300) cm3, blood loss was 256 (30-1200) ml. The I-PSS score after surgery decreased by an average of 18.3 points, the maximum urinary flow rate increased by 12 ml/s, the residual urine volume reduced from 147 to 28 ml. 35 (44%) patients underwent simultaneous operations (inguinal hernioplasty, cystolithotomy, etc.). There was one intraoperative complication, and 10 (12.6%) patients had postoperative complications. There were no conversions to open surgery. Incidental prostate cancer was detected in one patient. None of the patients required repeat surgery for infravesical obstruction. CONCLUSION: Extraperitoneoscopic adenomectomy is efficient, safe and reproducible surgical modality able to take the place of open surgery. There is a need for an evidence base to support the optimal choice between various minimally invasive techniques. Currently, laparoscopic procedure is more justified in patients with concomitant diseases, which can be simultaneously corrected.
[Mh] MeSH terms primary: Laparoscopy/methods
Prostatic Hyperplasia/surgery
Urologic Surgical Procedures, Male/methods
[Mh] MeSH terms secundary: Aged
Aged, 80 and over
Humans
Male
Middle Aged
Prostatic Hyperplasia/diagnostic imaging
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180309
[Lr] Last revision date:180309
[Js] Journal subset:IM
[Da] Date of entry for processing:180130
[St] Status:MEDLINE

  7 / 24406 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy

[PMID]: 29376596
[Au] Autor:Krivoborodov GG; Efremov NS; Bolotov AD
[Ad] Address:Department of Urology and Andrology, Medical Faculty of N.I. Pirogov RNRMU of Minzdrav of Russia, Moscow, Russia.
[Ti] Title:[Transabdominal and transrectal ultrasound assessment of intravesical prostatic protrusion].
[So] Source:Urologiia;(6):55-58, 2017 Dec.
[Is] ISSN:1728-2985
[Cp] Country of publication:Russia (Federation)
[La] Language:rus
[Ab] Abstract:RELEVANCE: Benign prostatic hyperplasia (BPH) is one of the most common urological diseases among men. Despite the noticeable positive effects of pharmacotherapy on the quality of urination in BPH, the presence of an intravesical obstruction (IVO) leads to discontinuation of conservative treatment in favor of surgical interventions. One of the features of prostate enlargement is the degree of its intravesical growth (intravascular prostatic protrusion, IPP). According to some studies, IPP value of 10 mm or more is indicative of IVO in virtually all men. AIM: To compare transabdominal and transrectal ultrasound measurement of IPP in men with BPH. MATERIALS AND METHODS: The study comprised 108 men aged 69+/-10 years (43 to 93 years) with lower urinary tract symptoms and BPH. Patients underwent a standard urological examination. The shape of the prostate, prostate volume and the measurements of the IPP were assessed using transabdominal and transrectal ultrasound. RESULTS: The IPP measurements obtained using transabdominal and transrectal ultrasound were 9.8+/-5.7 mm (1.1 to 28 mm) and 9.3+/-5.3 mm (0.5 to 26 mm), respectively. The IPP measurements evaluated by transabdominal and transrectal ultrasound were found comparable regardless of the prostate volume. CONCLUSION: Similar results in assessing PPI by both ultrasound modalities allow them to be used equally effectively.
[Mh] MeSH terms primary: Prostatic Hyperplasia/diagnostic imaging
[Mh] MeSH terms secundary: Adult
Aged
Aged, 80 and over
Humans
Male
Middle Aged
Ultrasonography/methods
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180309
[Lr] Last revision date:180309
[Js] Journal subset:IM
[Da] Date of entry for processing:180130
[St] Status:MEDLINE

  8 / 24406 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29522280
[Au] Autor:Zidan HE; Abdul-Maksoud RS; Elsayed WSH; Desoky EAM
[Ad] Address:Medical Biochemistry and Molecular Biology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
[Ti] Title:Diagnostic and prognostic value of serum miR-15a and miR-16-1 expression among egyptian patients with prostate cancer.
[So] Source:IUBMB Life;, 2018 Mar 09.
[Is] ISSN:1521-6551
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:Prostate cancer (PCa) is considered the most common malignancy in men. The aim of this study is to assess the role of serum miR-15a and miR-16-1 expression in PCa development, diagnosis and prognosis aiming to find a specific noninvasive biomarker. This study comprised 70 patients with PCa, 70 patients complaining of benign prostatic hyperplasia (BPH), 30 patients with chronic prostatitis and 70 controls. Circulating miR-15a and miR-16-1 expression was detected by real-time polymerase chain reaction. Prostate specific antigen levels were measured by enzyme-linked immunosorbent assay. The expression levels of serum miR-15a were decreased in PCa patients compared with controls, chronic prostatitis and BPH patients (0.43 0.12, 1.7 0.76, 1.56 0.34 and 1.53 0.65, respectively). The expression levels of serum miR-16-1 were decreased in PCa patients compared with controls, chronic prostatitis and BPH patients (0.55 0.23, 2.15 0.87, 2.08 0.54 and 1.96 0.61, respectively). Downregulation of miR-15a and miR-16-1 correlated with higher Gleason score (P = 0.002 and P = 0.006, respectively), higher tumor stage (P = 0.001 and P = 0.01, respectively), PCa metastasis (P = 0.002 and P = 0.025, respectively) and lymph node involvement (P = 0.02 and P = 0.007, respectively). Moreover, Receiver operating characteristic curve analysis revealed that combined miR-15a/miR-16-1 and PSA increased the sensitivity and specificity for the diagnosis of PCa (97.1% and 94.3%, respectively) more than prostate specific antigen alone (82.9% sensitivity and 75.7% specificity). Combined serum miR-15a/miR-16-1 expression and PSA level can be used as promising specific noninvasive biomarkers in the diagnosis and prognosis of PCa better than prostate specific antigen alone. 2018 IUBMB Life, 2018.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180309
[Lr] Last revision date:180309
[St] Status:Publisher
[do] DOI:10.1002/iub.1733

  9 / 24406 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29512089
[Au] Autor:Lee YJ; Oh SJ
[Ad] Address:Department of Urology, Seoul National University Bundang Hospital, Seongnam-si, Republic of Korea.
[Ti] Title:Calculi in the Prostatic Surgical Bed as a complication after Holmium Laser Enucleation of the Prostate.
[So] Source:Urol J;, 2018 Mar 07.
[Is] ISSN:1735-546X
[Cp] Country of publication:Iran
[La] Language:eng
[Ab] Abstract:PURPOSE: To report de novo calculi in the prostatic surgical bed as a complication of Holmium laser enucleation of the prostate (HoLEP). MATERIALS AND METHODS: Patients who underwent HoLEP and were enrolled in our Benign Prostatic Hyperplasia (BPH) Database Registry from July 2008 to December 2015 were reviewed. Cases of calculi removal in the prostatic surgical bed were identified. Clinical data, including preoperative evaluation, postoperative symptoms with a detailed history, urinalysis, pathology, cystourethroscopy, and stone analysis were collected and described. RESULTS: Eight patients were identified including one patient who underwent HoLEP at another hospital. Among the 877 patients in our BPH database, 7 (0.8%) underwent calculi removal in the prostatic surgical bed. Median age was 67.0 years. Median prostatic volume was 75.5mL. The most common symptom was severe stabbing urethral pain (n = 4), with a median of 13 months after HoLEP. Calculi were pedunculated in the prostatic surgical bed or in the bladder neck with a small mucosal connection. Pathology of the resected tissue showed granulation tissueformation and dystrophic calcification. CONCLUSION: Calculi in the prostatic surgical bed or the bladder neck after HoLEP have never been reported previously. Although it is very rare, recurrent urethral pain, persistent pyuria, and recurrent gross haematuria are signs for further investigation. Cystourethroscopy should be performed to rule out the presence of stones. Careful history taking and having an index of suspicion are important for the diagnosis.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180307
[Lr] Last revision date:180307
[St] Status:Publisher
[do] DOI:10.22037/uj.v0i0.3965

  10 / 24406 MEDLINE  
              first record previous record
select
to print
Photocopy
Taboga, Sebastio R
Full text

[PMID]: 29510085
[Au] Autor:Campos MS; Ribeiro NCS; de Lima RF; Santos MB; Vilamaior PSL; Regasini LO; Biancardi MF; Taboga SR; Santos FCA
[Ti] Title:Anabolic effects of chrysin on the ventral male prostate and female prostate of adult gerbils (Meriones unguiculatus).
[So] Source:Reprod Fertil Dev;, 2018 Mar 07.
[Is] ISSN:1031-3613
[Cp] Country of publication:Australia
[La] Language:eng
[Ab] Abstract:Chrysin is a bioflavonoid found in fruits, flowers, tea, honey and wine, which has antioxidant, anti-inflammatory, antiallergic and anticarcinogenic properties. This flavone has also been considered as beneficial for reproduction due its testosterone-boosting potential. Thus, the aim of this study was to evaluate the effects of chrysin on the prostate and gonads of male and female adult gerbils. In addition, a comparative analysis of the effects of testosterone on these same organs was conducted. Ninety-day-old male and female gerbils were treated with chrysin (50mgkg-1day-1) or testosterone cypionate (1mgkg-1week-1) for 21 days. The ventral male prostate and female prostate were dissected out for morphological, morphometric-stereological and ultrastructural assays. Testes and ovaries were submitted to morphological and morphometric---stereological analyses. Chrysin treatment caused epithelial hyperplasia and stromal remodelling of the ventral male and female prostate. Ultrastructurally, male and female prostatic epithelial cells in the chrysin group presented marked development of the organelles involved in the biosynthetic-secretory pathway, whereas cellular toxicity was observed only in female glands. Chrysin preserved normal testicular morphology and increased the number of growing ovarian follicles. Comparatively, testosterone treatment was detrimental to the prostate and gonads, since foci of prostatic intraepithelial neoplasia and gonadal degeneration were observed in both sexes. Thus, under the experimental conditions of this study, chrysin was better tolerated than testosterone in the prostate and gonads.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180306
[Lr] Last revision date:180306
[St] Status:Publisher
[do] DOI:10.1071/RD17456


page 1 of 2441 go to page                         
   


Refine the search
  Database : MEDLINE Advanced form   

    Search in field  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information